Tag

Glp 1s

All articles tagged with #glp 1s

business21 days ago•15 min saved

GLP-1 Weight-Loss Drugs Turn Office Small Talk Into HR Dilemmas

GLP-1 weight-loss drugs like Ozempic are turning casual office chatter into delicate HR and policy debates, as coworkers question body changes, while employers grapple with potential premium impacts and the ethics of sharing medical information. Even though individuals can discuss their own treatment, the conversations raise concerns about privacy, stigma, and fairness, leaving benefits teams balancing empathy with economics in a murky, evolving workplace landscape.

via Business Insider|

#business #glp-1s #health-insurance-costs

health25 days ago•3 min saved

Oral GLP-1 Pill Shows Promise in Reducing Heavy Drinking Days

A small phase II trial with 50 participants found that once-daily oral semaglutide reduced heavy drinking days and alcohol-related harms in adults with moderate to severe alcohol-use disorder, compared with placebo, though craving and average drinks per day did not decline; findings suggest GLP-1s could be a convenient harm-reduction option, but larger trials are needed to confirm efficacy.

via Gizmodo|

#alcohol-use-disorder #clinical-trial #glp-1s

health1 month ago•16 min saved

GLP-1 Weight-Loss Drugs May Bring Tiny Hair-Loss Risk

A Penn Medicine study of about 12,000 adults with type 2 diabetes newly started on GLP-1 drugs (including Ozempic and tirzepatide) found a small but higher risk of alopecia compared with users of other diabetes meds—about 1.6% developed hair loss over roughly two to three years, with GLP-1 users 37% more likely than SGLT-2 inhibitors and 68% more likely than DPP-4 inhibitors. The effect is mainly non-scarring and may be reversible; weight loss and possible nutrient deficiencies (iron, zinc) could drive a telogen effluvium mechanism. The study is observational and cannot prove causation; FDA labeling already lists alopecia as a potential adverse reaction, and ongoing dermatologic surveillance is advised.

via Gizmodo|

#alopecia #glp-1s #hair-loss

health1 month ago•17 min saved

Teens Turn to GLP-1 Weight-Loss Drugs as Surgery Falls Out of Favor

A UT Southwestern study of 204,148 youths aged 13–25 treated for obesity found GLP-1 medications (like semaglutide) are increasingly used, with exclusive GLP-1 use rising from 88.2% in 2022 to 96.1% in 2025–2026 and bariatric surgery dropping from 11.6% to 3.7%, signaling a rapid shift in obesity care toward medications for young people, though long‑term effects and treatment sequencing remain uncertain and these drugs should augment—not replace—comprehensive care.

via Gizmodo|

#bariatric-surgery #glp-1s #health

health1 month ago•17 min saved

High-Dose GLP-1 Drugs May Dim Joy, Doctors Warn

Doctors report three cases of anhedonia (loss of pleasure) in people taking the obese‑treating GLP-1 drug tirzepatide at very high doses (up to 15 mg/week). In all cases, symptoms eased after reducing the dose (and in one case adding an antidepressant), suggesting the effect is dose-related and manageable. The side effect is linked to GLP-1s’ influence on brain reward regions like the ventral tegmental area, though GLP-1 therapies remain associated with reduced depression symptoms overall. Clinicians emphasize monitoring motivation and pleasure during treatment, especially at higher doses, and note that this should not deter indicated use for obesity or type 2 diabetes while remaining vigilant and adjusting dosing as needed.

via Gizmodo|

#adverse-effects #anhedonia #glp-1s

health1 month ago•202 min saved

Cadaver fat injections ignite ethics debate as GLP-1 era reshapes bodies

A new body-contouring injectable called alloClae uses cadaver fat to restore volume in breasts, buttocks, and face, riding a surge in GLP-1 weight-loss users; it’s marketed as off-the-shelf fat grafting and can be injected in under an hour, but faces regulatory pushback (notably New York license denials) and ethical scrutiny over donor consent, with reports of complications like fat necrosis as demand grows and clinics scale up.

via CNN|

#alloclae #body-contouring #cadaver-fat

health1 month ago•17 min saved

Oral GLP-1 Weight-Loss Drugs Enter a Crowded, High-Stakes Race

Pharma firms are racing to bring pill-form GLP-1 weight-loss drugs to market, with aleniglipron and elecoglipron delivering about 11–12% weight loss over 36 weeks in Phase II, thanks to absorption-enhancers or small-molecule designs, while other candidates like Roche CT-996, Ascletis ASC30, and Viking VK2735 are in development. Even if approved, competition could lower prices and expand options beyond injections like Ozempic/Wegovy.

via Gizmodo|

#glp-1s #health #obesity

health2 months ago•16 min saved

GLP-1 Meds May Subtly Alter Smell and Taste, Study Finds

A large retrospective study across 170 centers found that people with type 2 diabetes using GLP-1 drugs (such as semaglutide found in Ozempic/Wegovy) were about 48% more likely to be diagnosed with smell or taste disturbances than non-users, though the absolute risk is tiny (0.37% vs 0.22%). The findings do not prove causation and call for more research, but clinicians and patients should monitor for anosmia, parosmia, and parageusia, as these could affect diet and quality of life; potential mechanisms may involve GLP-1 receptors in the brain and olfactory system, and early detection could enable interventions like olfactory training.

via Gizmodo|

#anosmia #glp-1s #health

health2 months ago•17 min saved

GLP-1 Drugs Misused by Eating-Disorder Patients, Study Finds

A University of Louisville–led study published in JAMA Psychiatry finds that among people with eating disorders, about 32% have used GLP-1 medications (e.g., semaglutide in Ozempic/Wegovy) at some point, and roughly 22% are current users—rates much higher than the general public—while about 10% report misuse (such as higher or non-prescribed dosages or sharing). GLP-1s are not indicated for eating disorders, and some individuals may be using them to achieve rapid weight loss or extreme restriction. The researchers emphasize the need for stricter pharmacovigilance as GLP-1 products broaden in form and market reach.

via Gizmodo|

#eating-disorders #glp-1s #health

health2 months ago•16 min saved

Ozempic Users See Drop in Daily Steps After GLP-1 Start

Using All of Us data, researchers analyzed 753 obesity patients prescribed GLP-1 medications (including semaglutide/Ozempic and tirzepatide) who had Fitbit data before/after starting therapy. After initiation, average daily steps fell from 5,047 to 4,487 and moderate-to-vigorous activity dropped from 28 minutes to 22 minutes, suggesting exercise promotion should accompany pharmacologic treatment. The findings are preliminary (to be presented at ENDO 2026) and older adults or those with musculoskeletal pain may be at higher risk for muscle loss.

via Gizmodo|

#exercise #fitbit #glp-1s

health2 months ago•4 min saved

GLP-1 Medications Show Promise in Alcohol Use Disorder, Awaiting Approval

A Danish Lancet trial found the GLP-1 drug semaglutide reduced alcohol consumption and heavy drinking days over 26 weeks, adding to a growing body of research that GLP-1s may curb cravings for various substances. However, these drugs are not approved for alcohol use disorder and are prescribed today for diabetes or obesity; ongoing studies in the U.S. and elsewhere are exploring effects on other addictions and whether benefits persist after stopping treatment. If future trials confirm efficacy and safety, GLP-1s could become a treatment option pending regulatory approval.

via Gizmodo|

#addiction #alcohol-use-disorder #clinical-trials

health3 months ago•16 min saved

GLP-1 Drugs Hint at Obesity Decline as Prescriptions Rise

New EPIC Research trackers using COSMOS data show GLP-1 prescriptions have risen fourfold since 2021, while obesity within the dataset declined from 42% to 41%, with GLP-1 users seeing a bigger drop (75% to 69%). While not nationally representative, the trend aligns with CDC estimates and other surveys that show rising GLP-1 use. Barriers like side effects, cost, and insurance limit adoption (about 12% of Americans), and cheaper generics abroad could arrive in five years. If adoption continues, obesity could decline further, though long-term effects remain uncertain.

via Gizmodo|

#epic-research #glp-1s #health

health4 months ago•17 min saved

GLP-1s for a Few Pounds: A Cautious Dive into the New Weight-Loss Trend

A Glamour-style piece documents how GLP-1 drugs once reserved for medical weight management are being used off-label for cosmetic goals, including compounded versions and microdosing via telehealth. It weaves patient anecdotes with medical perspectives, highlights risks like side effects and gut–microbiome effects, and shows a growing push-pull between health benefits and the influencer-driven hype. The author begins a low-dose Zepbound plan under a doctor’s supervision and reports initial weight loss, while stressing the need for cautious, evidence-based use as these drugs become more accessible.

via glamour.com|

#glp-1s #health #microdosing

lifestyle4 months ago•9 min saved

Thin and on GLP-1s: The Risks of Ozempic for Those Already Slim

The Looker examines the growing use of GLP-1 drugs like Ozempic among people who are already underweight or of normal BMI. Experts warn that using GLP-1s outside approved indications can trigger nutritional deficiencies, hormonal disruption, and loss of bone or muscle, and may worsen disordered eating or body-image issues. While celebrities discuss dramatic weight loss, clinicians emphasize these meds are not cosmetic supplements and should be used only under medical supervision. The piece also notes the social and mental-health implications and encourages seeking professional help for disordered eating.

via The Daily Beast|

#body-image #eating-disorders #glp-1s

health4 months ago•4 min saved

A GLP-1 Day: How to Pack Protein, Fiber, and Nutrients into Small Meals

Nutritionist Rob Hobson says people on GLP-1s should anchor meals in high-quality protein and pack nutrient-dense foods to counter reduced appetite. His Rule of Four—protein, a colorful fruit or vegetable, a healthy fat, and a whole-food carbohydrate—guides a day of meals, including breakfast options like a protein smoothie or eggs; lunches such as Buddha bowls with chicken or tofu and quinoa or tuna bowls; dinners like broth-based chicken noodle bowls, eggplant curry, or salmon with quinoa; and snacks focused on protein like edamame, cottage cheese with berries, or yogurt with granola. The aim is to maintain muscle, metabolism, and gut health with smaller, nutrient-dense portions.”,

via Business Insider|

#fiber #glp-1s #health